See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

The chef was able to ring the victory bell to mark the end of her cancer treatment and is getting her tastebuds back. Here's ...

Head and neck squamous cell carcinoma (HNSCC), the seventh most prevalent cancer globally, originates from the mucosal epithelium of the oral cavity, pharynx, and larynx. Traditional risk factors like ...

Knowledge of the association between human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma (OPSCC) is poor and ...

In Australia, anyone needing a facial prosthetic, such as a nose or ear, must pay for it themselves. However, those below the ...

First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.